Fig. 1: Dynamic BH3 profiling correctly predicts sensitivity to ALK inhibitors in NSCLC cell lines. | Cell Death & Disease

Fig. 1: Dynamic BH3 profiling correctly predicts sensitivity to ALK inhibitors in NSCLC cell lines.

From: Novel selective strategies targeting the BCL-2 family to enhance clinical efficacy in ALK-rearranged non-small cell lung cancer

Fig. 1: Dynamic BH3 profiling correctly predicts sensitivity to ALK inhibitors in NSCLC cell lines.

A DBP results in a representative panel of NSCLC (8 cell lines harboring oncogenic driver mutations [KRAS, EGFR, ALK, and MET] and 2 cell lines without detected alterations in these oncogenes [WT]). All the cell lines were incubated for 16 h with 1 µM of crizotinib, alectinib, brigatinib and lorlatinib. Results expressed as ∆% priming, representing the higher difference in cytochrome c released compared with control condition. Final concentrations of BIM BH3 peptide: 3, 1, 0.3, 0.1, 0.03 and 0.01 µM. B Results of cell death assay performed with Annexin V and DAPI staining after 96 h incubation with the same therapies and concentrations. C Correlation between % cell death at 96 h and ∆% priming at 16 h. D Receiver Operating Characteristic (ROC) curve analysis; treatments that exceeded the threshold of ∆% cell death > 20% were considered responders. The values obtained are from at least three independent experiments.

Back to article page